Lawmakers Push CDC to Track Vitamin K Refusals Amid Bleeding Risk

Vitamin K deficiency bleeding (VKDB) in infants, once a common and devastating cause of morbidity and mortality, became largely a historical footnote with the widespread adoption of prophylactic vitamin K administration at birth. This single intramuscular injection, typically 0.5 mg to 1 mg, ensures adequate clotting factor synthesis in newborns, whose immature livers and limited placental transfer of vitamin K leave them vulnerable.¹ The American Academy of Pediatrics (AAP) has recommended universal vitamin K prophylaxis since 1961, a recommendation based on decades of clear evidence demonstrating its efficacy and safety.²

But a recent investigation by ProPublica highlighted a concerning resurgence of VKDB cases, particularly the late-onset form, which typically manifests between two weeks and six months of age. This increase correlates directly with a rise in parental refusals of the vitamin K shot, often driven by misinformation regarding vaccine safety and perceived risks. The report detailed instances of infants suffering severe, irreversible brain damage or death from bleeding that could have been prevented by a simple injection.³

The Call for Data and Public Health Action

In response to the ProPublica report and mounting anecdotal evidence from paediatricians, a bipartisan group of US lawmakers has formally urged the Centers for Disease Control and Prevention (CDC) to begin tracking vitamin K shot refusals nationally. This initiative aims to quantify the scope of the problem, identify geographical hotspots of refusal, and inform targeted public health campaigns. Currently, no federal agency systematically collects this data, making it difficult to assess the true incidence of refusal and its impact on VKDB rates across the country.³

The mechanism of VKDB is straightforward: vitamin K is essential for the carboxylation of coagulation factors II, VII, IX, and X. Newborns have low vitamin K stores at birth, and breast milk contains insufficient amounts to compensate for this deficiency. Without the prophylactic shot, these factors remain inactive, leading to impaired coagulation and an increased risk of bleeding. Early VKDB occurs within the first 24 hours of life, classical VKDB between days 1 and 7, and late VKDB between weeks 2 and 6 months. Late VKDB is particularly dangerous, as it often presents with intracranial haemorrhage, carrying a mortality rate of 20% and significant neurological sequelae in survivors.¹

A 2013 study from Tennessee, for example, documented a 17-fold increase in late VKDB cases between 2003 and 2013, directly correlating with an increase in parental refusal of vitamin K prophylaxis. The study identified 17 cases of late VKDB during this period, with 16 of these infants having not received the vitamin K shot at birth. All 16 cases involved intracranial haemorrhage, and 2 infants died.⁴ This stark increase underscores the immediate public health threat posed by declining acceptance of this routine intervention. The data from individual states and institutions, while compelling, lacks the comprehensive national scope needed for a coordinated public health response.

The lawmakers' letter to the CDC emphasizes the need for robust data collection to understand the prevalence of refusals and the resulting health outcomes. They argue that without this information, public health officials cannot effectively address the underlying causes of refusal or implement evidence-based interventions to protect vulnerable infants. The request highlights the CDC's role in monitoring public health trends and coordinating responses to preventable diseases.³

The push for tracking vitamin K refusals mirrors efforts to monitor other vaccine hesitancy trends, such as measles, mumps, and rubella (MMR) vaccine uptake. The rationale is similar: identify areas with low coverage, understand the reasons for refusal, and develop targeted educational campaigns. For vitamin K, the immediate consequence of refusal is not herd immunity failure, but direct, severe harm to the individual infant. The intervention is a single, low-cost injection with a well-established safety profile. Adverse reactions are exceedingly rare and typically limited to minor injection site reactions.²

Still, the challenge lies in effectively communicating the critical importance of vitamin K prophylaxis to parents who may be exposed to misinformation. Clinicians often find themselves in difficult conversations, attempting to counter unfounded fears with scientific evidence. The lack of national data on refusal rates makes it difficult to quantify the scale of this communication challenge or to measure the effectiveness of different educational approaches. The proposed CDC tracking would provide a crucial baseline for these efforts.³

The open-label nature of this public health issue is the obvious caveat. There is no randomised controlled trial comparing refusal rates with and without tracking, nor would such a trial be ethical. The evidence for vitamin K's efficacy comes from historical data and observational studies comparing outcomes in populations that did and did not receive prophylaxis. The current push is not to re-evaluate the efficacy of vitamin K, but to understand the public health implications of its declining acceptance. The CDC's response to the lawmakers' request will determine the next steps in addressing this preventable public health crisis.